{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T11:52:12Z","timestamp":1783511532659,"version":"3.55.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2021,3,22]],"date-time":"2021-03-22T00:00:00Z","timestamp":1616371200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,3,22]],"date-time":"2021-03-22T00:00:00Z","timestamp":1616371200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["JP15K10093"],"award-info":[{"award-number":["JP15K10093"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Kyoto Prefectural University of Medicine"},{"DOI":"10.13039\/100016003","name":"Mie University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100016003","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1007\/s00262-021-02892-w","type":"journal-article","created":{"date-parts":[[2021,3,22]],"date-time":"2021-03-22T06:02:31Z","timestamp":1616392951000},"page":"3081-3091","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":41,"title":["Safety and antibody immune response of CHP-NY-ESO-1 vaccine combined with poly-ICLC in advanced or recurrent esophageal cancer patients"],"prefix":"10.1007","volume":"70","author":[{"given":"Takeshi","family":"Ishikawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7682-3295","authenticated-orcid":false,"given":"Shinichi","family":"Kageyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihiro","family":"Miyahara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuya","family":"Okayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Kokura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eiichi","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideo","family":"Yagita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshito","family":"Itoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Shiku","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,3,22]]},"reference":[{"issue":"11","key":"2892_CR1","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.1016\/S1470-2045(19)30626-6","volume":"20","author":"K Kato","year":"2019","unstructured":"Kato K, Cho BC, Takahashi M et al (2019) Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol 20(11):1506\u20131517. https:\/\/doi.org\/10.1016\/S1470-2045(19)30626-6","journal-title":"Lancet Oncol"},{"key":"2892_CR2","doi-asserted-by":"publisher","DOI":"10.1200\/jco.20.01888","author":"T Kojima","year":"2020","unstructured":"Kojima T, Shah MA, Muro K et al (2020) Randomized phase III KEYNOTE-181 study of pembrolizumab versus chemotherapy in advanced esophageal cancer. J Clin Oncol. https:\/\/doi.org\/10.1200\/jco.20.01888","journal-title":"J Clin Oncol"},{"key":"2892_CR3","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1016\/S1470-2045(16)00099-1","volume":"17","author":"JF Vansteenkiste","year":"2016","unstructured":"Vansteenkiste JF, Cho BC, Vanakesa T et al (2016) Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 17:822\u2013835. https:\/\/doi.org\/10.1016\/S1470-2045(16)00099-1","journal-title":"Lancet Oncol"},{"key":"2892_CR4","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1016\/S1470-2045(18)30254-7","volume":"19","author":"B Dreno","year":"2018","unstructured":"Dreno B, Thompson JF, Smithers BM et al (2018) MAGE-A3 immunotherapeutic as adjuvant therapy for patients with resected, MAGE-A3-positive, stage III melanoma (DERMA): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol 19:916\u2013929. https:\/\/doi.org\/10.1016\/S1470-2045(18)30254-7","journal-title":"Lancet Oncol"},{"key":"2892_CR5","doi-asserted-by":"publisher","first-page":"4248","DOI":"10.1158\/1078-0432.CCR-18-2867","volume":"25","author":"EA Mittendorf","year":"2019","unstructured":"Mittendorf EA, Lu B, Melisko M et al (2019) Efficacy and safety analysis of nelipepimut-S vaccine to prevent breast cancer recurrence: a randomized, multicenter, phase III clinical trial. Clin Cancer Res 25:4248\u20134254. https:\/\/doi.org\/10.1158\/1078-0432.CCR-18-2867","journal-title":"Clin Cancer Res"},{"issue":"7","key":"2892_CR6","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1093\/intimm\/dxw015","volume":"28","author":"B Temizoz","year":"2016","unstructured":"Temizoz B, Kuroda E, Ishii KJ (2016) Vaccine adjuvants as potential cancer immunotherapeutics. Int Immunol 28(7):329\u2013338. https:\/\/doi.org\/10.1093\/intimm\/dxw015","journal-title":"Int Immunol"},{"key":"2892_CR7","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1038\/nm.3105","volume":"19","author":"Y Hailemichael","year":"2013","unstructured":"Hailemichael Y, Dai Z, Jaffarzad N et al (2013) Persistent antigen at vaccination sites induces tumor-specific CD8+ T cell sequestration, dysfunction and deletion. Nat Med 19:465\u2013472. https:\/\/doi.org\/10.1038\/nm.3105","journal-title":"Nat Med"},{"issue":"3","key":"2892_CR8","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1586\/14760584.2015.966085","volume":"14","author":"KAO Martins","year":"2015","unstructured":"Martins KAO, Bavari S, Salazar AM (2015) Vaccine adjuvant uses of poly-IC and derivatives. Expert Rev Vaccines 14(3):447\u2013459. https:\/\/doi.org\/10.1586\/14760584.2015.966085","journal-title":"Expert Rev Vaccines"},{"key":"2892_CR9","doi-asserted-by":"publisher","first-page":"101414","DOI":"10.1016\/j.smim.2020.101414","volume":"30","author":"H Sultan","year":"2020","unstructured":"Sultan H, Salazar AM, Celis E (2020) Poly-ICLC, a multi-functional immune modulator for treating cancer. Semin Immunol 30:101414. https:\/\/doi.org\/10.1016\/j.smim.2020.101414","journal-title":"Semin Immunol"},{"issue":"1","key":"2892_CR10","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/s13045-017-0459-2","volume":"10","author":"S Mehrotra","year":"2017","unstructured":"Mehrotra S, Britten CD, Chin S et al (2017) Vaccination with poly(IC:LC) and peptide-pulsed autologous dendritic cells in patients with pancreatic cancer. J Hematol Oncol 10(1):82. https:\/\/doi.org\/10.1186\/s13045-017-0459-2","journal-title":"J Hematol Oncol"},{"issue":"1","key":"2892_CR11","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1158\/2326-6066.CIR-19-0545","volume":"8","author":"A Pavlick","year":"2020","unstructured":"Pavlick A, Blazquez AB, Meseck M et al (2020) Combined vaccination with NY-ESO-1 protein, poly-ICLC, and montanide improves antibody and cellular immune responses in patients with high-risk melanoma. Cancer Immunol Res 8(1):70\u201380. https:\/\/doi.org\/10.1158\/2326-6066.CIR-19-0545","journal-title":"Cancer Immunol Res"},{"issue":"5","key":"2892_CR12","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1093\/annonc\/mdy089","volume":"29","author":"ME Rodr\u00edguez-Ruiz","year":"2018","unstructured":"Rodr\u00edguez-Ruiz ME, Perez-Gracia JL, Rodr\u00edguez I et al (2018) Combined immunotherapy encompassing intratumoral poly-ICLC, dendritic-cell vaccination and radiotherapy in advanced cancer patients. Ann Oncol 29(5):1312\u20131319. https:\/\/doi.org\/10.1093\/annonc\/mdy089","journal-title":"Ann Oncol"},{"key":"2892_CR13","doi-asserted-by":"publisher","first-page":"6854","DOI":"10.1016\/j.vaccine.2009.09.018","volume":"27","author":"M Aoki","year":"2009","unstructured":"Aoki M, Ueda S, Nishikawa H et al (2009) Antibody responses against NY-ESO-1 and HER2 antigens in patients vaccinated with combinations of cholesteryl pullulan (CHP)-NY-ESO-1 and CHP-HER2 with OK-432. Vaccine 27:6854\u20136861. https:\/\/doi.org\/10.1016\/j.vaccine.2009.09.018","journal-title":"Vaccine"},{"key":"2892_CR14","doi-asserted-by":"publisher","DOI":"10.1186\/1479-5876-11-246","author":"S Kageyama","year":"2013","unstructured":"Kageyama S, Wada H, Muro K et al (2013) Dose-dependent effects of NY-ESO-1 protein vaccine complexed with cholesteryl pullulan (CHP-NY-ESO-1) on immune responses and survival benefits of esophageal cancer patients. J Transl Med. https:\/\/doi.org\/10.1186\/1479-5876-11-246","journal-title":"J Transl Med"},{"key":"2892_CR15","doi-asserted-by":"publisher","first-page":"7397","DOI":"10.1158\/1078-0432.CCR-06-1546","volume":"12","author":"S Kitano","year":"2006","unstructured":"Kitano S, Kageyama S, Nagata Y et al (2006) HER2-specific T-cell immune responses in patients vaccinated with truncated HER2 protein complexed with nanogels of cholesteryl pullulan. Clin Cancer Res 12:7397\u20137405. https:\/\/doi.org\/10.1158\/1078-0432.CCR-06-1546","journal-title":"Clin Cancer Res"},{"key":"2892_CR16","doi-asserted-by":"publisher","first-page":"1914","DOI":"10.1073\/pnas.94.5.1914","volume":"94","author":"YT Chen","year":"1997","unstructured":"Chen YT, Scanlan MJ, Sahin U et al (1997) A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc Natl Acad Sci U S A 94:1914\u20131918. https:\/\/doi.org\/10.1073\/pnas.94.5.1914","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2892_CR17","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1002\/ijc.1282","volume":"92","author":"AA Jungbluth","year":"2001","unstructured":"Jungbluth AA, Chen YT, Stockert E et al (2001) Immunohistochemical analysis of NY-ESO-1 antigen expression in normal and malignant human tissues. Int J Cancer 92:856\u2013860. https:\/\/doi.org\/10.1002\/ijc.1282","journal-title":"Int J Cancer"},{"key":"2892_CR18","doi-asserted-by":"publisher","first-page":"326","DOI":"10.3892\/mco.2012.40","volume":"1","author":"N Soga","year":"2013","unstructured":"Soga N, Hori Y, Yamakado K et al (2013) Limited expression of cancer-testis antigens in renal cell carcinoma patients. Mol Clin Oncol 1:326\u2013330. https:\/\/doi.org\/10.3892\/mco.2012.40","journal-title":"Mol Clin Oncol"},{"issue":"8","key":"2892_CR19","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1084\/jem.187.8.1349","volume":"187","author":"E Stockert","year":"1998","unstructured":"Stockert E, J\u00e4ger E, Chen Y-T et al (1998) A survey of the antibody immune response of cancer patients to a panel of human tumor antigens. J Exp Med 187(8):1349\u20131354. https:\/\/doi.org\/10.1084\/jem.187.8.1349","journal-title":"J Exp Med"},{"issue":"6","key":"2892_CR20","doi-asserted-by":"publisher","first-page":"3768","DOI":"10.4049\/jimmunol.0903649","volume":"185","author":"D Muraoka","year":"2010","unstructured":"Muraoka D, Kato T, Wang L et al (2010) Peptide vaccine induces enhanced tumor growth associated with apoptosis induction in CD8+ T cells. J Immunol 185(6):3768\u20133776. https:\/\/doi.org\/10.4049\/jimmunol.0903649","journal-title":"J Immunol"},{"issue":"3","key":"2892_CR21","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1172\/JCI97642","volume":"129","author":"D Muraoka","year":"2019","unstructured":"Muraoka D, Seo N, Hayashi T et al (2019) Antigen delivery targeted to tumor-associated macrophages overcomes tumor immune resistance. J Clin Invest 129(3):1278\u20131294. https:\/\/doi.org\/10.1172\/JCI97642","journal-title":"J Clin Invest"},{"key":"2892_CR22","doi-asserted-by":"publisher","first-page":"8862","DOI":"10.1073\/pnas.1133324100","volume":"100","author":"S Gnjatic","year":"2003","unstructured":"Gnjatic S, Atanackovict D, J\u00e4ger E et al (2003) Survey of naturally occurring CD4+ T cell responses against NY-ESO-1 in cancer patients: correlation with antibody responses. Proc Natl Acad Sci U S A 100:8862\u20138867. https:\/\/doi.org\/10.1073\/pnas.1133324100","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"2892_CR23","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1007\/s00535-015-1078-8","volume":"51","author":"Y Oshima","year":"2016","unstructured":"Oshima Y, Shimada H, Yajima S et al (2016) NY-ESO-1 autoantibody as a tumor-specific biomarker for esophageal cancer: screening in 1969 patients with various cancers. J Gastroenterol 51(1):30\u201334. https:\/\/doi.org\/10.1007\/s00535-015-1078-8","journal-title":"J Gastroenterol"},{"issue":"4","key":"2892_CR24","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1007\/s00262-020-02483-1","volume":"69","author":"M Ishihara","year":"2020","unstructured":"Ishihara M, Tono Y, Miyahara Y et al (2020) First-in-human phase I clinical trial of the NY-ESO-1 protein cancer vaccine with NOD2 and TLR9 stimulants in patients with NY-ESO-1-expressing refractory solid tumors. Cancer Immunol Immunother 69(4):663\u2013675. https:\/\/doi.org\/10.1007\/s00262-020-02483-1","journal-title":"Cancer Immunol Immunother"},{"issue":"5","key":"2892_CR25","first-page":"1645","volume":"39","author":"AS Levine","year":"1979","unstructured":"Levine AS, Sivulich M, Wiernik PH, Levy HB (1979) Initial clinical trials in cancer patients of polyriboinosinic-polyribocytidylic acid stabilized with poly-L-lysine, in carboxymethylcellulose [Poly(ICLC)], a highly effective interferon inducer. Cancer Res 39(5):1645\u20131650","journal-title":"Cancer Res"},{"issue":"2","key":"2892_CR26","doi-asserted-by":"publisher","first-page":"e001224","DOI":"10.1136\/jitc-2020-001224","volume":"8","author":"H Sultan","year":"2020","unstructured":"Sultan H, Wu J, Fesenkova VI et al (2020) Poly-IC enhances the effectiveness of cancer immunotherapy by promoting T cell tumor infiltration. J Immunother Cancer 8(2):e001224. https:\/\/doi.org\/10.1136\/jitc-2020-001224","journal-title":"J Immunother Cancer"},{"issue":"5","key":"2892_CR27","doi-asserted-by":"publisher","first-page":"2617","DOI":"10.1126\/science.1840703","volume":"178","author":"P Van Der Bruggen","year":"1991","unstructured":"Van Der Bruggen P, Traversari C, Chomez P et al (1991) A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 178(5):2617\u20132621. https:\/\/doi.org\/10.1126\/science.1840703","journal-title":"Science"},{"issue":"28","key":"2892_CR28","doi-asserted-by":"publisher","first-page":"2836","DOI":"10.1200\/JCO.2017.76.6212","volume":"36","author":"YY Janjigian","year":"2018","unstructured":"Janjigian YY, Bendell J, Calvo E et al (2018) CheckMate-032 study: efficacy and safety of nivolumab and nivolumab plus ipilimumab in patients with metastatic esophagogastric cancer. J Clin Oncol 36(28):2836\u20132844. https:\/\/doi.org\/10.1200\/JCO.2017.76.6212","journal-title":"J Clin Oncol"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-021-02892-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-021-02892-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-021-02892-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,11]],"date-time":"2021-10-11T12:06:01Z","timestamp":1633953961000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-021-02892-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,22]]},"references-count":28,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["2892"],"URL":"https:\/\/doi.org\/10.1007\/s00262-021-02892-w","relation":{},"ISSN":["0340-7004","1432-0851"],"issn-type":[{"value":"0340-7004","type":"print"},{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,22]]},"assertion":[{"value":"10 December 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 February 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 March 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"CHP-NY-ESO-1 was supplied by ImmunoFrontier Inc. (Osaka, Japan). Hiroshi Shiku is a stockholder of ImmunoFrontier Inc. Shinichi Kageyama, Yoshihiro Miyahara, and Hiroshi Shiku received research funds from ImmunoFrontier Inc. The other authors declare that they have no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in our studies involving human participants were conducted in accordance with Japanese Ethical Guidelines for Clinical Research, Japanese Guidelines for Medical and Health Research Involving Human Subjects, and the Helsinki declaration. The Institutional Review Board reviewed and approved the protocol and the informed consent documents and their amendments before use (Kyoto Prefectural University of Medicine approval number RBMR-C-941\u20132). All animal experiments were conducted in accordance with the Fundamental Guidelines for Proper Conduct of Animal Experiment and Related Activities in Academic Research Institutions and approved by Mie University (approval number 24\u201314).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Female BALB\/c mice aged 6\u201310\u00a0weeks were purchased from Japan SLC, Inc. (Shizuoka, Japan).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Animal source"}},{"value":"The CT26 cell line was purchased from the American Type Culture Collection (Virginia, USA). A human NY-ESO-1 transfected CT26 cell line was established as described previously [].","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Cell line authentication"}},{"value":"Written informed consent to participate in the study and for the use of clinical data for research and publication was obtained from all patients included in the studies: Kyoto Prefectural University of Medicine approval number: RBMR-C-941\u20132.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}